Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors: an analysis of 2765 patients from neoadjuvant clinical trials
Aim - To evaluate HER2-negative breast cancer (BC) with a low hormone receptor (HR) expression, with regard to pathological complete response (pCR) and survival, in comparison to triple-negative BC (TNBC) and strong HR-positive BC. - Methods - We compared negative [oestrogen (ER) and progesterone re...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
May 2021
|
| In: |
European journal of cancer
Year: 2021, Volume: 148, Pages: 159-170 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2021.02.020 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2021.02.020 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804921001039 
|
| Author Notes: | Sonia L. Villegas, Valentina Nekljudova, Nicole Pfarr, Jutta Engel, Michael Untch, Simone Schrodi, Frank Holms, Hans U. Ulmer, Peter A. Fasching, Karsten E. Weber, Christian Albig, Clemens Heinrichs, Frederik Marmé, Arndt Hartmann, Claus Hanusch, Wolfgang D. Schmitt, Jens Huober, Bianca Lederer, Marion van Mackelenbergh, Hans Tesch, Christian Jackisch, Mahdi Rezai, Peter Sinn, Bruno V. Sinn, John Hackmann, Marion Kiechle, Andreas Schneeweiss, Wilko Weichert, Carsten Denkert, Sibylle Loibl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1770882480 | ||
| 003 | DE-627 | ||
| 005 | 20240414193350.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210917s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2021.02.020 |2 doi | |
| 035 | |a (DE-627)1770882480 | ||
| 035 | |a (DE-599)KXP1770882480 | ||
| 035 | |a (OCoLC)1341421322 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Villegas, Sonia Lorena |e VerfasserIn |0 (DE-588)1166902331 |0 (DE-627)1030773203 |0 (DE-576)510957404 |4 aut | |
| 245 | 1 | 0 | |a Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors |b an analysis of 2765 patients from neoadjuvant clinical trials |c Sonia L. Villegas, Valentina Nekljudova, Nicole Pfarr, Jutta Engel, Michael Untch, Simone Schrodi, Frank Holms, Hans U. Ulmer, Peter A. Fasching, Karsten E. Weber, Christian Albig, Clemens Heinrichs, Frederik Marmé, Arndt Hartmann, Claus Hanusch, Wolfgang D. Schmitt, Jens Huober, Bianca Lederer, Marion van Mackelenbergh, Hans Tesch, Christian Jackisch, Mahdi Rezai, Peter Sinn, Bruno V. Sinn, John Hackmann, Marion Kiechle, Andreas Schneeweiss, Wilko Weichert, Carsten Denkert, Sibylle Loibl |
| 264 | 1 | |c May 2021 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.09.2021 | ||
| 520 | |a Aim - To evaluate HER2-negative breast cancer (BC) with a low hormone receptor (HR) expression, with regard to pathological complete response (pCR) and survival, in comparison to triple-negative BC (TNBC) and strong HR-positive BC. - Methods - We compared negative [oestrogen (ER) and progesterone receptor (PR) <1%], low-positive (ER and/or PR 1-9%) and strong-positive (ER or PR 10-100%) HR-expression in neoadjuvant clinical trial cohorts (n = 2765) of BC patients. End-points were disease-free survival (DFS), distant-disease free survival (DDFS) and overall survival (OS). We performed RNA sequencing on available tumour tissue samples from patients with low-HR expression (n = 38). - Results - Ninety-four (3.4%) patients had low HR-positive tumours, 1769 (64.0%) had strong HR-positive tumours, and 902 (32.6%) had TNBC. There were no significant differences in pCR rates between women with low HR-positive tumours (27.7%) and women with TNBC (35.5%). DFS and DDFS were also not different [for DFS, hazard ratio 1.26, 95%-CI (confidence interval) : 0.87-1.83, log-rank test p = 0.951; for DDFS, hazard ratio 1.17, 95%-CI: 0.78-1.76, log-rank test p = 0.774]. Patients with strong HR-positive tumours had a significantly lower pCR rate (pCR 9.4%; odds ratio 0.38, 95%-CI: 0.23-0.63), but better DFS (hazard ratio 0.48, 95%-CI: 0.33-0.70) and DDFS (hazard ratio 0.49, 95%-CI: 0.33-0.74) than patients with low HR-positive tumours. Molecular subtyping (RNA sequencing) of low HR-positive tumours classified these predominantly into a basal subtype (86.8%). - Conclusion - Low HR-positive, HER2-negative tumours have a similar clinical behaviour to TNBC showing high pCR rates and poor survival and also a basal-like gene expression signature. Patients with low HR-positive tumours should be regarded as candidates for therapy strategies targeting TNBC. | ||
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Breast neoplasms | |
| 650 | 4 | |a Cancer biomarkers | |
| 650 | 4 | |a ER-negative PR-negative HER2-negative breast cancer | |
| 650 | 4 | |a Hormone-dependent neoplasms | |
| 650 | 4 | |a Mammary cancer | |
| 650 | 4 | |a Neoadjuvant therapy | |
| 650 | 4 | |a Oestrogen receptors | |
| 650 | 4 | |a Progesterone receptors | |
| 650 | 4 | |a Triple-negative breast cancer | |
| 700 | 1 | |a Nekljudova, Valentina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pfarr, Nicole |e VerfasserIn |0 (DE-588)1063753309 |0 (DE-627)812590414 |0 (DE-576)422897701 |4 aut | |
| 700 | 1 | |a Engel, Jutta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Untch, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schrodi, Simone |e VerfasserIn |4 aut | |
| 700 | 1 | |a Holms, Frank |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ulmer, Hans U. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fasching, Peter A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weber, Karsten E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Albig, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heinrichs, Clemens |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Hartmann, Arndt |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hanusch, Claus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmitt, Wolfgang D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Huober, Jens |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lederer, Bianca |e VerfasserIn |4 aut | |
| 700 | 1 | |a van Mackelenbergh, Marion |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tesch, Hans |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jackisch, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rezai, Mahdi |d 1953- |e VerfasserIn |0 (DE-588)1107970350 |0 (DE-627)863713580 |0 (DE-576)475152131 |4 aut | |
| 700 | 1 | |a Sinn, Peter |d 1957- |e VerfasserIn |0 (DE-588)1022590944 |0 (DE-627)717004783 |0 (DE-576)365646342 |4 aut | |
| 700 | 1 | |a Sinn, Bruno |e VerfasserIn |0 (DE-588)107988131X |0 (DE-627)842397167 |0 (DE-576)453064752 |4 aut | |
| 700 | 1 | |a Hackmann, John |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kiechle, Marion |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Weichert, Wilko |d 1970-2023 |e VerfasserIn |0 (DE-588)123509106 |0 (DE-627)56134650X |0 (DE-576)293740461 |4 aut | |
| 700 | 1 | |a Denkert, Carsten |d 1969- |e VerfasserIn |0 (DE-588)118129929 |0 (DE-627)079261124 |0 (DE-576)291730604 |4 aut | |
| 700 | 1 | |a Loibl, Sibylle |e VerfasserIn |0 (DE-588)12433024X |0 (DE-627)085790508 |0 (DE-576)294122753 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 148(2021) vom: Mai, Seite 159-170 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors an analysis of 2765 patients from neoadjuvant clinical trials |
| 773 | 1 | 8 | |g volume:148 |g year:2021 |g month:05 |g pages:159-170 |g extent:12 |a Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors an analysis of 2765 patients from neoadjuvant clinical trials |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2021.02.020 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804921001039 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210917 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 27 | ||
| 998 | |g 1022590944 |a Sinn, Peter |m 1022590944:Sinn, Peter |d 910000 |d 912000 |d 50000 |e 910000PS1022590944 |e 912000PS1022590944 |e 50000PS1022590944 |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 23 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 60000 |d 61300 |d 50000 |e 60000PM132561972 |e 61300PM132561972 |e 50000PM132561972 |k 0/60000/ |k 1/60000/61300/ |k 0/50000/ |p 13 | ||
| 999 | |a KXP-PPN1770882480 |e 3979073947 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","given":"Sonia Lorena","display":"Villegas, Sonia Lorena","family":"Villegas"},{"role":"aut","display":"Nekljudova, Valentina","given":"Valentina","family":"Nekljudova"},{"family":"Pfarr","display":"Pfarr, Nicole","given":"Nicole","role":"aut"},{"role":"aut","given":"Jutta","display":"Engel, Jutta","family":"Engel"},{"given":"Michael","display":"Untch, Michael","family":"Untch","role":"aut"},{"role":"aut","given":"Simone","display":"Schrodi, Simone","family":"Schrodi"},{"family":"Holms","display":"Holms, Frank","given":"Frank","role":"aut"},{"family":"Ulmer","given":"Hans U.","display":"Ulmer, Hans U.","role":"aut"},{"role":"aut","family":"Fasching","display":"Fasching, Peter A.","given":"Peter A."},{"role":"aut","family":"Weber","given":"Karsten E.","display":"Weber, Karsten E."},{"display":"Albig, Christian","given":"Christian","family":"Albig","role":"aut"},{"role":"aut","display":"Heinrichs, Clemens","given":"Clemens","family":"Heinrichs"},{"family":"Marmé","given":"Frederik","display":"Marmé, Frederik","role":"aut"},{"display":"Hartmann, Arndt","given":"Arndt","family":"Hartmann","role":"aut"},{"family":"Hanusch","display":"Hanusch, Claus","given":"Claus","role":"aut"},{"role":"aut","display":"Schmitt, Wolfgang D.","given":"Wolfgang D.","family":"Schmitt"},{"role":"aut","family":"Huober","display":"Huober, Jens","given":"Jens"},{"role":"aut","family":"Lederer","given":"Bianca","display":"Lederer, Bianca"},{"given":"Marion","display":"van Mackelenbergh, Marion","family":"van Mackelenbergh","role":"aut"},{"display":"Tesch, Hans","given":"Hans","family":"Tesch","role":"aut"},{"role":"aut","given":"Christian","display":"Jackisch, Christian","family":"Jackisch"},{"given":"Mahdi","display":"Rezai, Mahdi","family":"Rezai","role":"aut"},{"role":"aut","given":"Peter","display":"Sinn, Peter","family":"Sinn"},{"role":"aut","family":"Sinn","display":"Sinn, Bruno","given":"Bruno"},{"display":"Hackmann, John","given":"John","family":"Hackmann","role":"aut"},{"role":"aut","given":"Marion","display":"Kiechle, Marion","family":"Kiechle"},{"role":"aut","display":"Schneeweiss, Andreas","given":"Andreas","family":"Schneeweiss"},{"role":"aut","display":"Weichert, Wilko","given":"Wilko","family":"Weichert"},{"display":"Denkert, Carsten","given":"Carsten","family":"Denkert","role":"aut"},{"role":"aut","display":"Loibl, Sibylle","given":"Sibylle","family":"Loibl"}],"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"May 2021"}],"name":{"displayForm":["Sonia L. Villegas, Valentina Nekljudova, Nicole Pfarr, Jutta Engel, Michael Untch, Simone Schrodi, Frank Holms, Hans U. Ulmer, Peter A. Fasching, Karsten E. Weber, Christian Albig, Clemens Heinrichs, Frederik Marmé, Arndt Hartmann, Claus Hanusch, Wolfgang D. Schmitt, Jens Huober, Bianca Lederer, Marion van Mackelenbergh, Hans Tesch, Christian Jackisch, Mahdi Rezai, Peter Sinn, Bruno V. Sinn, John Hackmann, Marion Kiechle, Andreas Schneeweiss, Wilko Weichert, Carsten Denkert, Sibylle Loibl"]},"recId":"1770882480","title":[{"title_sort":"Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors","subtitle":"an analysis of 2765 patients from neoadjuvant clinical trials","title":"Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors"}],"language":["eng"],"physDesc":[{"extent":"12 S."}],"id":{"doi":["10.1016/j.ejca.2021.02.020"],"eki":["1770882480"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 17.09.2021"],"relHost":[{"corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}],"origin":[{"publisher":"Elsevier ; Pergamon Press","dateIssuedDisp":"1992-","dateIssuedKey":"1992","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]"}],"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"part":{"volume":"148","text":"148(2021) vom: Mai, Seite 159-170","year":"2021","extent":"12","pages":"159-170"},"id":{"eki":["266883400"],"zdb":["1468190-0"],"issn":["1879-0852"]},"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"disp":"Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors an analysis of 2765 patients from neoadjuvant clinical trialsEuropean journal of cancer","recId":"266883400","language":["eng"],"titleAlt":[{"title":"EJC online"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["28.1992 -"]}]} | ||
| SRT | |a VILLEGASSOTHERAPYRES2021 | ||